Abstract
Osteoarthritis (OA) and rheumatoid arthritis (RA) are two of the most common chronic inflammatory joint diseases, for which there remains a great clinical need to develop safer and more efficacious pharmacological treatments. The pathology of both OA and RA involves multiple tissues within the joint, including the synovial joint lining and the bone, as well as the articular cartilage in OA. In this review, we discuss the potential for the development of oligonucleotide therapies for these disorders by examining the evidence that oligonucleotides can modulate the key cellular pathways that drive the pathology of the inflammatory diseased joint pathology, as well as evidence in preclinical in vivo models that oligonucleotides can modify disease progression.
Original language | English |
---|---|
Article number | 902 |
Journal | Biomedicines |
Volume | 9 |
Issue number | 8 |
Early online date | 27 Jul 2021 |
DOIs | |
Publication status | Published - 31 Aug 2021 |
Bibliographical note
Funding Information:Funding: This research was funded by Versus Arthritis, grant number 21530.
Keywords
- Antisense
- Bone
- Cartilage
- Oligonu-cleotides
- Osteoarthritis
- Rheumatoid arthritis
- Synovitis
- Therapeutics
ASJC Scopus subject areas
- Medicine (miscellaneous)
- General Biochemistry,Genetics and Molecular Biology